View : 735 Download: 182
Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products
- Title
- Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products
- Authors
- Lee, Soyoung; Kim, Han Wool; Kim, Kyung-Hyo
- Ewha Authors
- 김경효; 김한울
- SCOPUS Author ID
- 김경효; 김한울
- Issue Date
- 2016
- Journal Title
- JOURNAL OF KOREAN MEDICAL SCIENCE
- ISSN
- 1011-8934
1598-6357
- Citation
- JOURNAL OF KOREAN MEDICAL SCIENCE vol. 31, no. 12, pp. 1937 - 1942
- Keywords
- Antibody; Hepatitis A Virus; Hepatitis B Virus; Intravenous Immunoglobulin
- Publisher
- KOREAN ACAD MEDICAL SCIENCES
- Indexed
- SCIE; SCOPUS; KCI
- Document Type
- Article
- Abstract
- The worldwide seroprevalence of hepatitis A virus (HAV) and hepatitis B virus (HBV) has changed over the last two decades, indicating a declining incidence of HAV and HBV infections. Therefore, vaccinations against HAV and HBV are recommended for unimmunized people before traveling to an endemic area. Unfortunately, primary antibody deficiency (PAD) patients can only obtain humoral immunity through intravenous immunoglobulin G (IVIG) replacement and not from vaccination because of a defect in antibody production. However, few studies have analyzed the titers of antibodies against HAV or HBV in IVIG products. In this study, the titers of anti-HAV and anti-HBs antibodies were measured in nineteen lots of IVIG products from five manufacturers from three countries (A, B from Korea; C, D from Japan; and E from the USA), and trough titers in plasma were estimated. Concentrations of anti-HAV antibody ranged from 1,888-8,927 mIU/mL and estimated trough titers exceeded the minimal protective value in all evaluated vertical bar V vertical bar G products. Concentrations of anti-HBs antibody ranged from 438-965 mIU/mL in products A and B and were 157, 123, and 1,945 mIU/mL in products C, D, and E, respectively. Estimated trough titers in products A, B, and E exceeded the minimal protective value but those in products C and D did not reach this threshold. These data demonstrated that available IVIG products generally provide sufficient antibodies against HAV and HBV to protect patients with PAD, although the trough concentrations of anti-HBs antibody in two IVIG products did not reach the minimum protective value.
- DOI
- 10.3346/jkms.2016.31.12.1937
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
-
Antibodies against hepatitis a and hepatitis b virus in intravenous immunoglobulin products.pdf(394.03 kB)
Download
- Export
- RIS (EndNote)
- XLS (Excel)
- XML